Evaluation on post treatment pain in patients undergoing Root Canal Treatment with 3 agents Lignocaine,sodium Diclofenac, Ketorolac tromethamine.

Phase 1

Conditions: Pulpitis,

Registration Number: CTRI/2020/09/027635

Lead Sponsor: Dr Meghna Kothari

Brief Summary: Introduction:-Pain of endodontic origin is of concern to both the patient and the clinician. The expectation of a painful experience can increase the patientâ€™s anxiety levels, making treatment more difficult. Management of endodontic pain is one of the challenging aspects in endodontics.

Aim:-A comparative evaluation of anesthetic efficiency of nerve block along with adjuvant intraligamentary injection of lignocaine, diclofenac sodium, and ketorolac tromethamine on reduction of the intra appointment endodontic pain in normal and hypertensive patients with irreversible pulpitis.

Materials and Methods: 198 patients were randomly allocated into three groups. Group 1 â€“ hypertensive patients with irreversible pulpitis, Group B â€“ healthy individuals with irreversible pulpitis . Preoperative VAS scale was recorded. The IANB nerve block was given to all the allotted patients and intraligamnetry injection od either lignocaine, diclofenac sodium, or ketorolac tromethamine was injected before access opening before the start of the procedure, while the intraligamentary injection was administered before commencing the endodontic. access opening was carried out. The visual analog scale (VAS) was used to evaluate the pain score at baseline and after getting drop into the pulp chamber

results:-There Is a Statistically Significant Difference Seen between Diclofenac Sodium And Ketorolac Tromethamine within and inter Group 1 and group2 while no Statistically Significant Difference Seen When Compared To Lignocaine Among Group1 And Group2.

Detailed Description: Not available

Recruitment & Eligibility

Status: Other

Sex: All

Target Recruitment: 198

Inclusion Criteria

1.The patients between 18 to 60 years of age with mandibular teeth where mandibular nerve block is required to anesthetize the tooth.
2.Patients diagnosed with irreversible pulpitis with hot tooth.
3.Patients having history of stage 1 and 2 hypertension and undergoing regular treatment.
4.Patients having no systemic diseases other hypertension would be included.
5.Patient should have actively experiencing moderate to severe pain on VAS scale of 5 or more.
6.Teeth with no well defined periapical radiolucency seen on radiographic examination.
7.Patients with history of previous initiation root canal therapy.
8.A written informed consent will be taken from all the patients and only those patients ready to sign the consent letter.

Exclusion Criteria

Patients with known hypersensitivity to diclofenac sodium, ketorolac tromethamine and lignocaine.
Patients who are pregnant or lactating 3.
Patients who are contraindicated for NSAIDs 4.
Patients who have undergone cardiac surgery in last 6 months 5.
Patients with fractured or visibly cracked tooth, developmental anomalies, pathology or open apex related to study teeth.
Patients who had taken NSAIDS within 24 hrs before administration of study drug.
(antibiotic as such no criteria required) â€ƒ.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Intraligamentary Injections are known to reduce the pain after giving nerve block in cases of irreversible pulpitis. The generally used agent is lignocaine but other drugs like diclofenac sodium and ketorolac tromethamine are also proved to reduce the intra-appointment pain	At Baseline and \| Second after getting drop inside the pulp chamber

Secondary Outcome Measures

Name	Time	Method
To evaluate post operative pain following Intraligamentry Injection using lignocaine, diclofenac sodium, ketorolac tromethamine	At Baseline

Trial Locations

Locations (1): Dept of Conservative dentistry and Endodntics, K M shah denatal college and hospital
🇮🇳
Vadodara, GUJARAT, India
Dept of Conservative dentistry and Endodntics, K M shah denatal college and hospital
🇮🇳Vadodara, GUJARAT, India
dr Meghna Kothari
Principal investigator
9823008220
meghnakothari13@gmail.com